The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection Fraction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 488 participants.

Also called NCT05508035

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 488 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05508035
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Poland (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05508035. Randomized; double masking; primary purpose treatment. Start 2023-07-13 (actual); primary completion 2028-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection Fraction
Acronym
CRACOVIA-HF
Condition
Heart Failure With Moderately Reduced Ejection Fraction
Intervention (Drug)
Sacubitril / Valsartan
Intervention (Drug)
Ramipril
Lead sponsor
John Paul II Hospital, Krakow (class: other)

Record details

Record id
cardio:ct-nct05508035
Content hash
87a7c8ee7e7ca685b5d40a504f8754d175fafba078b0cb663267325e31421ced